Compass Therapeutics (CMPX) Set to Release Earnings on Wednesday

Compass Therapeutics (NASDAQ:CMPX) is expected to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Compass Therapeutics to post earnings of ($0.12) per share and revenue of $0.23 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 9:30 AM ET.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, analysts expect Compass Therapeutics to post ($0.47) EPS for the current fiscal year and ($0.49) EPS for the next fiscal year.

Compass Therapeutics Stock Performance

CMPX opened at $0.79 on Monday. The business has a 50 day moving average price of $1.46 and a 200 day moving average price of $3.23. Compass Therapeutics has a twelve month low of $0.73 and a twelve month high of $6.88. The firm has a market cap of $141.64 million, a P/E ratio of -1.97 and a beta of 1.06.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on CMPX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Thursday, October 15th. Wedbush set a $4.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, September 23rd. Citigroup reaffirmed a “market outperform” rating on shares of Compass Therapeutics in a report on Wednesday, September 23rd. Guggenheim lowered their target price on shares of Compass Therapeutics to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, September 23rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Compass Therapeutics in a research note on Wednesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.25.

Compass Therapeutics Company Profile

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving immune responses in patients with cancer.

Its lead product candidate, CTX-471, is a fully human monoclonal antibody designed to activate CD137, also known as 4-1BB. CD137 is a co-stimulatory receptor found on immune cells, including T cells and natural killer cells.